Corcept Therapeutics is a biopharmaceutical firm focused on developing treatments for conditions involving hormonal imbalances, cancer-related disorders, metabolic disease, and neurological conditions. The company markets Korlym, an oral drug for managing elevated blood sugar caused by excess cortisol in adult Cushing's syndrome patients with type 2 diabetes who have either undergone unsuccessful surgery or are ineligible for it. Corcept is also advancing several experimental cortisol-targeting molecules in clinical trials, including candidates under investigation for fatty liver disease and amyotrophic lateral sclerosis.
1Y: 81.12 (+10.4%) · range 32.15–123.57
entry readiness 79 · GOOD SETUP · exit proximity 0
Value area 86.97–126.38 · 81% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +4.49% | +14.47% | mature |
| 40d | +7.67% | +14.47% | mature |